| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $162,244 | 5 | 100 |
Sells | $0 | 0 | 0 |
| Luo Peter | Chief Executive Officer | 3 | $148,744 | 0 | $0 | $148,744 |
| DO CUONG V | director | 1 | $7,500 | 0 | $0 | $7,500 |
| Tam Man Kin | Chief Financial Officer | 1 | $6,000 | 0 | $0 | $6,000 |
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and …
Over the last 12 months, insiders at Adagene Inc. have bought $162,244 and sold $0 worth of Adagene Inc. stock.
On average, over the past 5 years, insiders at Adagene Inc. have bought $162,244 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Luo Peter (Chief Executive Officer) — $148,744. DO CUONG V (director) — $7,500. Tam Man Kin (Chief Financial Officer) — $6,000.
The last purchase of 2,000 shares for transaction amount of $6,000 was made by Tam Man Kin (Chief Financial Officer) on 2026‑09‑23.
| 2026-09-23 | Tam Man Kin | Chief Financial Officer | 2,000 0.0054% | $3.00 | $6,000 | -10.10% | ||
| 2026-09-16 | Luo Peter | Chief Executive Officer | 20,290 0.0536% | $3.15 | $63,980 | -13.25% | ||
| 2026-08-14 | DO CUONG V | director | 2,000 0.0045% | $3.75 | $7,500 | -16.89% | ||
| 2026-08-05 | Luo Peter | Chief Executive Officer | 279 0.0006% | $3.65 | $1,018 | -24.11% | ||
| 2026-08-04 | Luo Peter | Chief Executive Officer | 22,966 0.0611% | $3.65 | $83,746 | -11.81% |
| Increased Positions | 8 | +40% | 1M | +21.74% |
| Decreased Positions | 7 | -35% | 4M | -67.74% |
| New Positions | 4 | New | 1M | New |
| Sold Out Positions | 4 | Sold Out | 4M | Sold Out |
| Total Postitions | 21 | +5% | 3M | -46.01% |